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Abstract 
 
Alzheimer’s disease (AD) is the most common type of dementia in the 
elderly. Neurofibrillary tangles (NFTs), a major pathological hallmark of 
AD, are composed of tau protein that is hyperphosphorylated by 
Cyclin-dependent kinase 5 (Cdk5) and Glycogen Synthase Kinase 3β 
(GSK3β). NFTs also contain Wiskott-Aldrich syndrome protein family 
verprolin-homologous protein 1 (WAVE1) and Collapsin Response 
Mediator Protein 2 (CRMP2). Although Cdk5 is known to phosphorylate 
tau, WAVE1, and CRMP2, the significance of this with respect to NFT 
formation remains to be elucidated. 
 In this study, I examined the involvement of phosphorylated CRMP2 and 
WAVE1 in phospho-tau aggregates using a triple-transgenic (3xTg; 
APPswe/PS1M146V/tauP301L) AD mouse model. First, I verified the 
co-localization of phosphorylated WAVE1 and CRMP2 with aggregated 
hyperphosphorylated tau in the hippocampus at 23 months. Biochemical 
analysis revealed the inclusion of phosphorylated WAVE1, CRMP2 and 
tau in the sarkosyl-insoluble fractions of hippocampal homogenates. To 
further test the significance of phosphorylation of these proteins, I 
administered All Trans-Retinoic Acid (ATRA) to the 3xTg mice, which 
down-regulates the Cdk5 and GSK3β activities. In ATRA-treated mice, 
fewer and smaller tau aggregates were observed than those in 
non-ATRA-treated mice. In addition, ATRA inhibited inflammatory 
lesions in 3xTg mice such as astrocytosis and microgliosis.  
 To investigate the role of phosphorylation of CRMP2 in tau aggregation, I 
crossed 3xTg mice with CRMP2 knock-in (CRMP2KI/KI) mice in which 
the Cdk5 phosphorylation site Ser522 was mutated into an Ala residue. 
Histological and biochemical analyses showed that phosphorylation of 
CRMP2 is involved in tau aggregation in hippocampus of 3xTg mice. 
These results suggest the possibility of CRMP2 as a novel therapeutic 
target molecule to prevent tau pathology.
 6 
Chapter 1. Introduction 
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1.1 Alzheimer’s disease 
Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is the 
most common type of dementia in the elderly. In 1906, Alois Alzheimer, a 
Bavarian psychiatrist, firstly defined and described the clinicopathological 
syndrome as Alzheimer’s disease (Selkoe 2001). The major pathological 
hallmarks of AD in the brain are extracellular senile plaques and 
intracellular neurofibrillary tangles (NFTs), which lead to synaptic loss and 
neuronal death (Selkoe 1999). Clinical characteristics of AD are poorly 
failure of memory, findings include confusion, poor judgment, language 
disturbance, agitation and withdrawal. (Bird TM 2015).  
 Senile plaques are formed by the accumulation of amyloid-β (Aβ), which 
is generated by amyloid precursor protein (APP) processing (Selkoe 2001). 
NFTs are composed of paired helical filaments (PHFs). The main 
component of PHFs has been identified as hyperphosphorylated tau. This 
phosphorylation is carried out by several kinases, including 
Cyclin-dependent kinase 5 (Cdk5), Glycogen Synthase Kinase 3β (GSK3β), 
cdc2, JNK and CaMKⅡα (Ihara et al. 1986; Wang et al. 2007).  
 Early-onset dementia is distinguished from late-onset dementia depending 
on the age of symptom onset. Early-onset dementia starts onset of symptom 
at the age of less than 65 years old. On the other hand, late-onset dementia 
begins onset of symptom at the age over 65 years old. Familial mutations, 
autosomal dominant inheritances, have been identified in PS1, PS2, and 
APP genes in early-onset of dementia. Most of these mutations show 
increase in amount of Aβ  and/or ratio of Aβ 42/ Aβ 40 (Selkoe and Hardy 
2016).    
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1.3 Tau 
Tau, one of the microtubule-associated proteins (MAPs), is involved in 
microtubule dynamics. More than 80 phosphorylation sites are identified in 
tau. The phosphorylated form of tau is not capable of binding to the 
microtubule, and thus induces the microtubule destabilization. Due to 
alternative splicings which skip exon 2,3 and 10, there is 6 isoforms of tau 
(Fig. 1.2). All 6 isoforms of Tau are expressed in human brain, however 
only 3 isoforms of 4R is expressed in mouse brain excepted for newborn 
neurons (Wang and Mandelkow 2016).  
 Tau aggregation is characterized in some neurodegenerative disorders 
such as Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), 
corticobasal degeneration (CBD), Pick disease (PiD), frontotemporal 
dementia with Parkinsonism-17 (FTDP-17). Interestingly, tauopathies are 
categorized into 3 groups based on the tau isoform in aggregates: 4R 
tauopathies (PSP, CBD), 3R tauopathies (PiD), 3+4R tauopathies (AD) 
(Wang and Mandelkow 2016).  
 Especially in FTDP-17, firstly familial mutation P301L was identified in 
the MAPT gene which is the gene encoding tau (Grover A et al. 1999). 
After that, a number of mutations were confirmed by analysis in the 
microtubule binding domain. However, there is no report to identify 
familial mutations on tau in AD patients. Recently a tau mutant A152T, 
one of the risk factors of tauopathy including AD, was identified (Coppola 
et al. 2012). Nevertheless, the mechanism of tau aggregation is not 
understood well. 
 Tau generally receives post-translational modifications such as 
phosphorylation, glycosylation, ubiquitination, and truncation. Some 
modifications may be related to aggregation of tau and trigger of 
pathogenesis (Martin L et al. 2011). However it is still under controversy. 
In addition, one hypothesis based on miss localization of tau indicated that 
misssorting of tau into dendrites would be one of the early signs of 
neurodegeneration. But its mechanism is unclear (Wang and Mandelkow 
2016).  
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1.4 Collapsin response mediator protein 2 (CRMP2) and 
Wiskott-Aldrich syndrome protein family verprolin-homologous 
protein 1 (WAVE1) 
Recently, it has been reported that NFTs in the brains of patients with AD 
contain other components, such as Wiskott-Aldrich syndrome protein 
family verprolin-homologous protein (WAVE) (Takata et al. 2009) and 
collapsin response mediator protein 2 (CRMP2) (Gu, Hamajima, and Ihara 
2000) (Yoshida, Watanabe, and Ihara 1998).  
 CRMP2, which mediates Semaphorin3A (Sema3A) signaling, regulates 
axon guidance and growth cone collapse (Uchida et al. 2005). In AD, a 
form of CRMP2 that is phosphorylated by Cdk5 and GSK3β has been 
identified as a component of NFTs and is implicated in the development of 
AD (Cole et al. 2007; Gu et al. 2000). Cdk5 primarily phosphorylates 
CRMP2 at the Serine 522 residue and GSK3β secondly phosphorylates 
CRMP2 at the Threonine 509, 514 and 518 residues (Uchida et al. 2005). 
The phosphorylated form of CRMP2 disrupts association of CRMP2 with 
tubulin (Uchida et al. 2005). Previous study based on proteomics analysis 
has been shown that CRMP2 binds to tau/p-tau as an interacting partner 
(Wang et al. 2017). However, the role of CRMP2 phosphorylation in AD 
pathology, especially in tau aggregation, remains poorly understood.  
 On the other hand, a few previous studies have revealed the relationship 
between Aβ and CRMP2. Aggressive Aβ toxicity increases 
phosphorylation level of CRMP2 in vivo and inhibition of its 
phosphorylation indicated protective effect against Aβ-induced 
neurotoxicity (Cole et al. 2007; Isono et al. 2013). These lines of evidence 
imply that CRMP2 possibly plays important roles in downstream of 
amyloid pathology.  
Recently, it is suggested that CRMP2 is involved in not only 
neurodegenerative diseases but also psychiatric disorders. Brain-specific 
knockout of CRMP2 showed schizophrenia-like behaviors (Zhang et al. 
2016).   
 WAVE1 is a key regulatory protein of actin-related protein (Arp) 2/3 
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complex-mediated actin assembly and modifies the morphology of spines, 
small protrusions from the neuronal dendrite that receive input from axon 
terminals (Kim et al. 2006; Sanchez et al. 2009). Phosphorylations of 
WAVE1 by Cdk5 at the sites of Ser310, Ser397 and Ser441 residues inhibit 
its regulation of actin polymerization (Ceglia et al. 2010).  
 These proteins regulate cytoskeletal dynamics through phosphorylation by 
Cdk5, however, their significance in NFT formation remains poorly 
understood. 
 
  
 14 
1.5 All-trans retinoic acid (ATRA) 
Deprivation of vitamin A results in development of AD (Corcoran et al. 
2004; Misner et al. 2001). All-trans retinoic acid (ATRA), which is a 
derivative of vitamin A, regulates the expression level of target genes 
through the activation of retinoic acid receptors (RARs) and retinoid X 
receptors (RXRs) (Germain et al. 2006). Retinoids play critical role in CNS 
development and differentiation. ATRA has anti-inflammatory effects to 
suppress production of several cytokines (Dheen et al. 2005).  
 There are several reports that demonstrate the effect of ATRA to amyloid 
processing. ATRA treatment elevated the mRNA and protein level of 
α-secretase in IMR-32 cells which is a human neuroblastoma cell line and 
downregulated β-secretase in vitro and in vivo (Koryakina et al. 2009; 
Wang et al. 2015). These lines of evidence suggested that ATRA would 
accelerate non-amyloidgenic pathways and attenuate production of Aβ. 
Administration of ATRA to APP/presenilin-1 (PS1) transgenic mice 
prevented amyloid plaque accumulation and inhibited activation of 
astrocytes and microglia surrounding amyloid pathology (Ding et al. 2008). 
Moreover, ATRA suppresses the kinase activities of Cdk5 and GSK3β. 
Thus, ATRA pharmacotherapy may be effective for preventing the 
progression of AD. However the effect of ATRA treatment on tau 
pathology remains unclear. 
  
 In the present study, I used the triple-transgenic (3xTg; 
APPswe/PS1M146V/tauP301L) AD mouse model (Oddo et al. 2003), 
which shows both plaques and NFTs, to further clarify the involvement of 
CRMP2 and WAVE1 and the effect of ATRA treatment in tau pathology. 
In addition, to investigate the role of phosphorylation of CRMP2 in tau 
aggregation, I crossed 3xTg mice with CRMP2 knock-in (KI/KI) mice, in 
which the Cdk5 phosphorylation site Ser522 was mutated into Ala to 
eliminate Cdk5 phosphorylation and analyzed tau pathology.   
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Chapter 2. Materials and Methods 
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Materials 
2.1 Antibodies and Compounds 
The following antibodies were used: anti-phosphorylated tau AT8 (Thermo, 
MN1020), anti-tau5 (Chemicon, MAB361), anti-phosphorylated tau 
Ser404 (AnaSpec, 28023-025), anti-tau (Sigma, SAB4501821), 
anti-phosphorylated CRMP2 Ser522 (ECM Bioscience, CP2191), 
anti-phosphorylated CRMP2Thr509 and anti-CRMP2 (9F) produced by our 
laboratory (Yamashita et al. 2012), anti-phosphorylated WAVE1 (Sigma, 
W2768), anti-WAVE1 (Millipore, Q2187170), anti-β-actin (Sigma,A2103), 
anti-GFAP (Sigma, G3893), and anti-Iba1 (Wako, 019-19741). Alexa 488 
goat anti-mouse IgG (Invitrogen), Alexa 488-goat anti-rabbit IgG 
(Invitrogen) and Alexa 594 goat anti-mouse IgG (Invitrogen) were used as 
secondary fluorescent probes for histological analysis. Goat anti-rabbit 
IgG-HRP (Santa Cruz Biotechnology sc-2004) and goat anti-mouse 
IgG-HRP (Santa Cruz Biotechnology sc-2005) were used as secondary 
antibodies for western blot analysis. ATRA was purchased from Wako 
(Osaka, Japan). ATRA dissolved in normal saline containing 5% DMSO 
was given three times weekly by intraperitoneal injection (20 mg/kg). 
Non-ATRA treated group received an equal volume of 5% DMSO in saline. 
Administration of ATRA to 3xTg mice started at the age of 22 months and 
continued for 4 weeks.  
 
2.2 Animals 
Mice used in the experiments were housed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee at Waseda 
University. Triple-transgenic mice were generated as previously described 
(Oddo et al. 2003). Briefly, we co-microinjected two transgenes  
(APPswe; KM670/671NL and tau P301L;4R0N under the control of the 
Thy1.2 promoter) into embryos harvested from PSM146V knock-in mice 
(Oddo et al. 2003; Guo 1999). APPswe/PS1ΔE9 mice were generated as 
previously described (Jankowsky et al. 2004;,Jankowsky et al. 2001). This 
transgenic mouse line expresses mouse/human (Mo/Hu) chimeric APP695  
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harboring the Swedish (KN594/595ML) mutation gene and human PS1 
gene (PS1ΔE9) under the control of mouse prion promoter, which drives a 
high level of protein in neurons and astrocytes of the central nervous 
system (CNS). CRMP2 knock in mice (CRMP2KI/KI) were generated as 
previously described (Yamashita et al. 2012). 
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Biochemical analysis 
2.3 Preparation of sarkosyl-insoluble fraction 
Mouse brains were dissected at 4℃, frozen on dry ice, and stored at -80℃. 
Brain samples were homogenized in 10 nmol/L HEPES buffer (pH 7.0) 
containing 0.32 M/L sucrose and cocktail of proteases and phosphatases 
inhibitors (Roche Applied, Berkeley, CA, USA) as described (Kitamura et 
al. 1998), and centrifuged at 12,000×g for 30 minutes. The pellets were 
used for preparation of the sarkosyl-insoluble fraction, and the supernatants 
were used as the soluble cytosol fraction. The pellets were washed with the 
same homogenization buffer three times, and a Bradford protein assay kit 
(Bio-Rad, Tokyo, Japan) was used to determine the protein concentration. 
Then, 100µg of proteins was re-homogenized in 500µL of the 
homogenization buffer, which included one-tenth of volume of 10% 
sarkosyl solution, and samples were then vortexed and incubated for 1hour 
at 37℃. After incubation, the samples were centrifuged at 100,000×g for 1 
hour and were dissolved with the homogenization buffer and Laemmli 
sample buffer. Then supernatants were subsequently analyzed as the 
sarkosyl-insoluble fraction (Takata et al. 2009).  
 
2.4 Western blot 
Equal amounts of protein were separated on 12.5% SDS-PAGE gel and 
transferred to a polyvinylidene difluoride membrane (Millipore). The 
membranes were blocked in 3% BSA in TBS buffer containing 0.05% 
Tween20 (TBST) and were incubated with 1st antibody. It was at room 
temperature for 1 hour. After washing the membrane with TBST, incubated 
with HRP-conjugated 2nd antibody. After reaction with ECL Plus reagent 
(GE healthcare), signals were detected by LAS-3000 (Fujifilm, Tokyo, 
Japan). Image J 1.47 (NIH, Bethesda, MD, USA) was used for 
densitometry analysis. 
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Histological analysis 
2.5 Immunostaining 
Mice were anesthetized with diethyl ether and were perfused with 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS). Brain 
samples were fixed with 4% PFA in PBS overnight at 4℃. After 
dehydration in 20% sucrose, sections were embedded in Optimal Cutting 
Temperature Compound (OCT company). Sections were cut to 14 µm 
thickness on a cryostat and retained at -20℃ until use for immunostaining. 
The sections were washed in PBS containing 0.01% TritonX-100 (PBST), 
and incubated in blocking buffer (0.1% PBST with 3% horse serum). After 
an overnight incubation with the primary antibodies at 4℃, sections were 
incubated with the secondary antibodies for 1 hour. They were then washed 
with PBS and mounted using Vectashield with 
4’,6-diamidino-2-phenylindole (DAPI) (Vector Labs, Burlingame, CA, 
USA) for nuclear staining. For AT8 single staining, sections were subjected 
to pretreatment at 121℃ for 5 minutes with citrate buffer solution (0.1M 
citric acid, 0.1M sodium citrate) to achieve high staining efficiency. For the 
microscopic analysis of the number and area of p-tau-, p-CRMP2-, and 
p-WAVE1-positive signals, I measured the area and counted the positive 
signals in the CA1 of 3xTg mice with Image J. To evaluate positive signals 
accurately, more than 3 images were analyzed, and the number and area 
were averagred.  
 
2.6 BF-168 staining 
Staining using BF-168 (Wako Pure Chemical Industries), a chemical 
compound that specifically recognizes amyloid (Okamura et al. 2004), was 
conducted according to the manufacturer’s protocol. 
 
2.7 Statistical analysis 
All data represent the mean ± SEM. Statistical analyses were performed 
using the Student’s t-test and one-way ANOVA with Tukey’s multiple 
comparison test. Differences were considered significant at p<0.05. 
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Chapter 3. Results-1 Involvement 
of Cdk5 substrates in NFTs 
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Chapter 3.1-4.4 refers to Watamura et al. 2016 
 
3.1 Co-localization of the phosphorylated forms of WAVE1, CRMP2, 
and tau in the hippocampal neurons of 3xTg mice. 
Previous studies showed that CRMP2 is a PHF-associated molecule in the 
AD brain (Ihara et al. 1986; Gu et al. 2000; Yoshida 1998). Thus, I 
analyzed the immunoreactivity of phosphorylated tau (p-tau) and CRMP2 
(p-CRMP2) in the hippocampi of 3xTg mice at 13 and 23 months of age. 
Using laser confocal microscopy, I frequently detected aggregated p-tau in 
the hippocampus of 23-month-old 3xTg mice and observed faint 
p-tau-positive signals in hippocampus of 13-month-old 3xTg mice (Fig. 
3.1A). Therefore, I performed double immunostaining with anti-p-tau and 
anti-p-CRMP2 antibodies. No co-localized staining was observed in wild 
type (WT) mice. I rarely observed co-localized signals at 13 months as 
previously reported (Yoshida et al. 1998). In 23-month-old 3xTg mice, I 
frequently observed the co-localization of aggregated p-tau and p-CRMP2, 
which were phosphorylated by Cdk5 at Ser 522 (Fig. 3.1B) and GSK3β at 
Thr 509 (Fig. 3.1C). These results coincide with previous studies (Gu et al. 
2000; Takata et al. 2009). Next I analyzed the immunoreactivity of the 
phosphorylated forms of WAVE1 (p-WAVE1) at Ser397, which is 
phosphorylated by Cdk5 (Ceglia et al. 2010). I found co-localization of 
aggregated p-tau and p-WAVE1 in the hippocampal CA1 neurons of 
23-month-old 3xTg mice, but this co-localization was rarely observed in 
13-month-old 3xTg mice and not seen at all in 23-month-old WT mice 
which is used as negative control and examined the specificity of the 
antibody (Fig. 3.1D).   
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Fig. 3.1 Co-localization of the phosphorylated forms of WAVE1 
(p-WAVE1), CRMP2 (p-CRMP2), and tau (p-tau) in 23-month-old 
triple transgenic (3xTg) mice.  
A, p-tau immunostaining (clone AT8; green) in the hippocampus of 3xTg mice 
reveals formation of neurofibrillary tangles (NFTs) at the age of 23 months. 
p-Tau-positive signals are slightly visible at 13 months. Scale bar: 100 μm. (Inset 
scale bar: 50 μm). B-C, Double immunostaining of p-tau (clone AT8; B-C; red) 
and p-CRMP2 (Ser522; B; green, and Thr509; C; green) in the hippocampal CA1 
region. Co-localized signals of p-tau and p-CRMP2 are observed in 
23-month-old 3xTg mice. No co-localized signals are observed in 23-month-old 
WT mice. D, Co-localization of p-tau (clone AT8; D; red) and p-WAVE1 (Ser397; 
D; green) is also observed in the hippocampal CA1 region of 23-month-old 3xTg 
mice. No co-localized signals were observed in 23-month-old WT mice. In all 
cases, co-localized signals are rarely observed in 13-month-old 3xTg mice (n = 2 
for each staining). Scale bar: 40 μm. Arrows indicate co-localized signals.  
(Watamura et al. 2016)  
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3.2 Presence of p-WAVE1, p-CRMP2, and p-tau in the 
sarkosyl-insoluble fraction of hippocampal homogenates from 3xTg 
mice  
To clarify whether insoluble fractions from hippocampus of 23-month old 
3xTg mice contain phosphorylated forms of WAVE1, CRMP2 and tau, I 
prepared sarkosyl-insoluble fractions of hippocampal homogenates from 
23-month-old 3xTg and WT mice, and from 13-month-old 3xTg mice. In 
AD patient brain, sarkosyl extraction is used for analyzing insoluble tau 
aggregates as a standard protocol (Ren and Sahara 2013). The lysates were 
analyzed to determine whether p-tau, p-CRMP2, and p-WAVE1 were 
present (Fig. 3.2A). Although none of these were detected in the brains of 
WT mice, I detected strong signals for p-tau (Fig. 3.2B, C), p-CRMP2 (Fig. 
3.2D-F) and p-WAVE1 (Fig. 3.2G, H) in the sarkosyl-insoluble fractions 
from 23-month-old 3xTg mice, and faint signals of tau, p-CRMP2 (T509), 
CRMP2, and WAVE1 in 13-month-old 3xTg mice.  
  

 26 
Fig. 3.2 Sarkosyl-insoluble fraction of hippocampal homogenates from 
23-month-old triple transgenic (3xTg) mice. A, An immunoblot analysis 
shows the inclusion of the phosphorylated forms of WAVE1 (p-WAVE1), CRMP2 
(p-CRMP2), and tau (p-tau) (n = 3 per group). No p-WAVE1, p-CRMP2, or p-tau 
is detected in hippocampal homogenates from wild type (WT) mice. B-H, The 
statistical analysis of phosphorylated (B, D, E, G) and total tau, CRMP2, and 
WAVE1 (C, F, H) (*p< 0.05 by a one-way ANOVA). (Watamura et al. 2016) 
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3.3 Accumulation of p-CRMP2 and p-WAVE1 in dystrophic neurites  
In AD pathology, dystrophic neurites surrounding amyloid plaques have 
been described (Cummings et al. 1992;,Vickers et al. 2006). These are 
thought to indicate active neuritic damages, possibly including 
degenerating fibers or fibers that are regenerating due to a reactive process 
(Saitoh and Horsburgh et al. 1993). Dystrophic neurites show 
immunoreactivity to multiple synaptic and cytoskeletal proteins, such as 
APP, synaptophysin, ubiquitin, and p-tau (Blanchard et al. 2003). In the 
AD model mice, the inclusion of phosphorylated forms of CRMP2 and 
WAVE1 in dystrophic neuritis surrounding amyloid plaques remained 
unclear. Therefore, I investigated the immunoreactivity of p-CRMP2 and 
p-WAVE1 in dystrophic neurites in the cerebral cortices of 23-month-old 
3xTg mice. I also investigated p-CRMP2 and p-WAVE1 
immunoreactivities in the APPswe/PS1ΔE9 AD mouse model at 17 months 
of age at which these mice have widespread mature amyloid plaques in the 
cerebral cortex and hippocampus (Jankowsky et al. 2004). To stain 
amyloid plaques, I used BF-168, which specifically binds to Aβ (Okamura 
et al. 2004). I found that the immunoreactivities of p-WAVE1 and 
p-CRMP2 co-localized with p-tau, and were located near peripheral 
amyloid plaques in the cerebral cortices of 23-month-old 3xTg mice (Fig. 
3.3A) and 17-month-old APPswe/PS1ΔE9 (Fig. 3.3B).   
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Chapter 4. Results-2 The effect of 
ATRA in 3xTg mice 
 30 
4.1 ATRA treatment modifies tau phosphorylation 
Previous studies have indicated that tau is abnormally hyperphosphorylated 
by Cdk5 and GSK3β, and that it accumulates as intraneuronal tangles that 
directly correlates with neurodegeneration (Iqbal et al. 2005; Shelton et al. 
2004). ATRA prevents the accumulation of amyloid plaques and APP 
processing into Aβ through down-regulation of Cdk5 activity in APP/PS1 
mice (Ding et al. 2008). Therefore, I administrated ATRA intraperitoneally 
to 3xTg mice for 4 weeks to prevent tau phosphorylation and to attenuate 
the aggregation of p-tau. Histological analysis using anti-p-tau (AT8) 
antibody showed a decreased number of AT8 positive signals in 
ATRA-treated mice compared with non-ATRA-treated mice (Fig. 4.1A). I 
then compared the number and area of AT8 positive signals between 
ATRA-treated and non-ATRA treated mice. Quantitative image analyses 
showed that the number and area of AT8 positive signals as identified by 
p-tau were significantly decreased in area CA1 of the hippocampi in 
ATRA-treated mice compared with those in non-ATRA-treated mice (Fig. 
4.1B, C). Additionally, in ATRA-treated mice, histological analysis using 
other tau antibodies showed that these positive signals tended to decrease 
compared with those in non-ATRA treated mice (Fig. 4.1D, E).  
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4.2 The immunoreactivities of p-tau aggregation including p-CRMP2 
and p-WAVE1 are decreased by ATRA treatment 
I found that aggregated p-tau in CA1 of 23 month-3xTg mice included 
phosphorylated form of CRMP2 and WAVE1 (Fig. 3.2) and then ATRA 
treatment reduced the number of p-tau aggregation (Fig. 4.1). Hence, to 
investigate the effect of ATRA regarding other components of p-tau 
aggregation, I analyzed the co-localization of p-tau and p-CRMP2 
immunoreactivities between the ATRA-treated and non-treated 23 
month-old 3xTg mice. I performed double immunostaining using anti- 
p-tau and anti-p-CRMP2 at Ser 522 (p-CRMP2(S522)) (Fig. 4.2A). The 
statistical analysis indicated a relative decrease in the number (Fig. 4.2D) 
and a significant decrease in the area (Fig. 4.2E) of co-localized 
immunoreactivities. However, no difference in the co-localized 
immunoreactivities of p-tau and p-CRMP2 at Thr 509 (p-CRMP2(T509)) 
was observed between the ATRA-treated and non-ATRA-treated 3xTg 
mice (Fig. 4.2B). ATRA-treated mice tended to show a decrease in the 
number and area of co-localized immunoreactivities (Fig. 4.2F, G).  
  Because I observed that p-tau co-localized with p-WAVE1 in 
23-month-old 3xTg mice (Fig. 3.1D), I analyzed the co-localization of 
p-tau and p-WAVE1 immunoreactivities. Decrease in the number and area 
of co-localized immunoreactivities was observed in ATRA-treated mice 
(Fig. 4.2C). Quantitative analyses of area and number showed significant 
differences in the extent of p-tau co-localization with p-WAVE1 between 
ATRA-treated and non-ATRA-treated 3xTg mice (Fig. 4.2H, I).  
 To confirm the down-regulation of Cdk5 and GSK3β activities by ATRA 
treatment, I analyzed the soluble fraction from ATRA-treated and 
non-treated 23 month-old-3xTg mice homogenates (Fig. 4.3A). I found that 
the phosphorylation level of tau at Ser202/Thr205 recognized by AT8 
antibody and depending on Cdk5 activity, decreased in ATRA-treated mice 
compared with those in non-ATRA treated mice (Fig. 4.3B) (Hashiguchi et 
al. 2002). ATRA also relatively inactivated GSK3β by increasing the 
phosphorylation at Ser9 (Fig. 4.3C) (Dajani et al. 2001). 
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Phosphorylation of this site by Akt has an inhibitory effect of GSK3β. No 
statistically significance was seen about phosphorylation and total level of 
CRMP2 and WAVE1 in soluble fraction (data not shown). 
 Next, I analyzed the effect of ATRA in the sarkosyl-insoluble fractions 
from hippocampi of 3xTg mice (Fig. 4.3D). An immunoblot showed that 
significant reduction of p-tau was confirmed between ATRA-treated and 
non-treated 3xTg mice (Fig. 4.3E). However, predominant change 
regarding the amount of total tau was not detected (Fig. 4.3F). Amounts of 
phospho- and total CRMP2 and WAVE1 tended to decrease in 
ATRA-treated 3xTg mice compared with non-ATRA-treated mice (Fig. 
4.3G-K). These results suggest that the administration of ATRA inhibits 
activity of Cdk5 and GSK3β and attenuates the formation of phospho-tau 
aggregation including phosphorylated forms of CRMP2 and WAVE1 in the 
3xTg mouse brain. 
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Fig. 4.3 The effect of ATRA treatment in soluble fractions and 
sarkosyl-insoluble fractions. 
A, Immunoblot of soluble fraction from the hippocampi of ATRA-treated and 
non-ATRA-treated 3xTg mice. Significant difference of p-tau was confirmed (B) 
and phosphorylation of GSK3β tend to increase by ATRA treatment (C) (n = 3 
per group). Actin was used to show equal loading. 
Immunoblot of the sarkosyl- insoluble fraction from the hippocampi of 
ATRA-treated and non-ATRA-treated 3xTg mice (D). p-tau significantly decrease 
(E) and phospho- and total CRMP2 and WAVE1 signals tend to be lower in the 
homogenates from ATRA-treated 3xTg mice compared with non-ATRA-treated 
mice (G-K) (n = 3 per group). However, no change regarding the amount of total 
tau has not been detected (F). (Watamura et al. 2016)  
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4.3 Suppression of activated astrocytes and microglia by ATRA 
treatment 
Activated microglia and astrocytes have been observed surrounding 
amyloid and tau pathology in patients with AD and transgenic AD model 
mice (Itagaki et al. 1989; Yoshiyama et al. 2007). An in vitro study showed 
that retinoic acid could inhibit the production of inflammatory cytokines 
and cytotoxic molecules through the suppression of activated microglia 
(Dheen et al. 2005). Further, ATRA treatment inhibited the activation of 
astrocytes and microglia around amyloid plaque in APP/PS1 mice (Ding et 
al. 2008). Therefore, I investigated the effect of ATRA on activated 
astrocytes and microglia in the hippocampal CA1 region of ATRA-treated 
and non-treated 3xTg mice. In order to analyze activated astrocytes in CA1, 
I performed immunostaining using the anti-GFAP antibody which is an 
astrocyte marker. GFAP staining revealed reactive astrocytes, characterized 
by an increase in the thickness and branching of astrocytes in the brains of 
non-ATRA-treated 3xTg mice. Fewer reactive astrocytes were seen in the 
ATRA-treated 3xTg mice (Fig. 4.4A). Quantitative analysis showed an 
approximately 45% decrease in the GFAP-positive area in ATRA-treated 
3xTg mice compared with the non-ATRA-treated ones (Fig. 4.4B). No 
significant difference in the number of astrocytes was observed between 
the ATRA-treated and non-treated 3xTg mice (Fig. 4.4C).   
 Additionally, I examined microglial activation in the hippocampal CA1 
region of ATRA-treated and non-ATRA-treated 3xTg mice. The anti-Iba1 
antibody was used as a microglial marker. I observed a decrease in 
activated microglia, which display bushy, thickened, and branched 
processes, in area CA1 of non-ATRA-treated 3xTg mice compared with 
ATRA-treated ones (Fig. 4.4D). The CA1 hippocampal area occupied by 
microglia in ATRA-treated 3xTg mice showed an approximately 40% 
decrease compared with those in non-ATRA-treated mice (Fig. 4.4E). 
Further, the number of microglia in area CA1 showed an approximately 
35% decrease (Fig. 4.4F). These results indicated that ATRA treatment 
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inhibited the activation of astrocytes and microglia in the hippocampal 
CA1 region of the 3xTg mouse brains. 
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Fig. 4.4 Immunostaining of astrocytes and microglia in the 
hippocampus of all-trans retinoic acid (ATRA)-treated and 
non-ATRA-treated triple-transgenic (3xTg) mice. A, D, the activation of 
astrocytes and microglia is inhibited by ATRA treatment. The area (B) and 
number (C) of astrocytes are indicated. The area of astrocytes in ATRA-treated 
3xTg mice is significantly decreased compared with non-ATRA-treated 3xTg 
mice. The area (E) and number (F) of microglia are indicated. The area and 
number of microglia in ATRA-treated 3xTg mice is significantly decreased 
compared with non-ATRA-treated 3xTg mice. Scale bar: 100 μm. (Inset scale 
bar: 25μm) (n = 3 for each staining). 
Area and number of GFAP and Iba1 positive signals within the hippocampal 
area were measured using Image J.(Watamura et al. 2016) 
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Chapter 5. Results-3 The role of 
CRMP2 phosphorylation in NFT 
formation 
 42 
5.1 Histological analysis of 3xTg;CRMP2KI mice 
To investigate whether phosphorylation of CRMP2 contributes to tau 
aggregation or not, I crossed 3xTg mice with CRMP2KI mice and observed 
tau pathology. CRMP2KI mice exhibit constitutive active form of CRMP2 
because the phosphorylated site by Cdk5 (Serine 522) is converted to 
Alanine (Yamashita et al. 2012). P-tau (AT8) signals in CA1 of 
hippocampi of 3xTg;CRMP2KI mice were decreased compared with those 
in 3xTg mice (Fig. 5.1A,B). Signals of total tau antibody in CA1 of 
3xTg;CRMP2KI mice also tended to be attenuated (Fig. 5.1C,D). In 
addition, to analyze relationship between amyloid deposition and CRMP2 
phosphorylation, I performed immunostaining using anti-Aβ antibody 
(6E10) which detects N-terminal domain of Aβ. Since there was no 
difference of amyloid deposition between 3xTg mice and 3xTg;CRMP2KI 
mice, inhibition of CRMP2 phosphorylation did not affect amyloid 
pathology in hippocampus of 3xTg mice (Fig. 5.1E,F).  
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5.2 Biochemical analysis of 3xTg;CRMP2KI mice 
I conducted biochemical analysis to check amount of tau and p-tau in the 
TBS-soluble fraction and sarkosyl insoluble fraction of 3xTg and 
3xTg;CRMP2KI mice. In the TBS-soluble fraction, phosphorylation level 
of tau in 3xTg;CRMP2KI mice was predominantly lowered compared with 
those in 3xTg mice (Fig. 5.2A,B). Moreover, total tau level in hippocampi 
of 3xTg;CRMP2KI mice was approximately 3-fold increased (Fig.5.2A,C). 
In sarkosyl-insoluble fraction, I detected no significant difference of p-tau 
between 3xTg mice and 3xTg;CRMP2KI mice (Fig. 5.2D,E). However, I 
observed decreased total tau level in 3xTg;CRMP2KI mice compared with 
those in 3xTg mice (Fig. 5.2D,F). These results suggest that 
phosphorylation of CRMP2 by Cdk5 is involved in the formation of NFTs 
but not deposition of amyloid plaques.  
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Chapter 6. Discussion 
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6.1 Cdk5 substrates in NFT of 3xTg and other AD model mice.  
It has been reported that p-CRMP2 is one of the components of NFTs in 
the brains of patients with AD (Takata et al. 2009;,Gu et al. 2000;,Yoshida 
1998). In the present study, I demonstrated the co-localization of p-tau 
immunoreactivity with p-CRMP2 and p-WAVE1 in 23-month-old 3xTg 
mice (Figs, 3.1,3.3). I further demonstrated the inclusion of p-tau, 
p-CRMP2, and p-WAVE1 in the sarkosyl-insoluble fractions of 
hippocampal homogenates from 3xTg mice (Fig. 3.2). I revealed that a 
novel NFT-associated protein, WAVE1, is phosphorylated at the 
Cdk5-phosphorylation site (Kim et al. 2006). Since phosphorylated 
tau/CRMP2 /WAVE1 would exhibit insolubility along with progression of 
AD, potent alteration in these phosphorylation levels has not been detected 
in the soluble fraction of 23-month-old 3xTg mice compared with 
13-month-old 3xTg and 23-month-old WT mice (data not shown). 
  An initial study demonstrated that 3xTg mice first develop extracellular 
accumulations of Aβ deposits at 6 months old in the frontal cortex and in 
other cortical and hippocampal regions at 12 months old, whereas p-tau 
pathology is first apparent in CA1 neurons at 12 to 15 months of age (Oddo 
et al. 2003). However, no amyloid or tau pathology was detected at these 
time points in the present study. Histologically, I detected a low frequency 
of amyloid pathology in the cerebral cortex at 16-23 months and tau 
pathology in the hippocampus and amygdala at 23 months in the 3xTg 
mice. This discrepancy might be explained by changes in the amounts of 
transgenes expressed across generations of transgenic mice. 
  A previous study suggested that mice with a single overexpressed 
transgene of human tau (JNPL3) or mice with human APP overexpression 
(Tg2576) do not show p-WAVE accumulation in NFTs and in dystrophic 
neurites (Takata et al. 2009). In the present study, I detected p-WAVE1 
signals in NFTs in the hippocampi of 3xTg mice and in dystrophic neurites 
in aged 3xTg and APPswe/PS1ΔE9 mice. These results suggest that 
excessive Aβ may induce an increase in WAVE1 phosphorylation, and that 
the combination of Aβ and tau pathologies causes the inclusion of 
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accumulated p-WAVE1 in NFTs in the hippocampal CA1 region. However, 
JNPL3 mice, which only have tau pathology, show p-CRMP2 in the 
hippocampus upon histological examination (Takata et al. 2009). Therefore, 
one of the mechanisms of CRMP2 phosphorylation may be independent of 
amyloid pathology. However, my biochemical studies detected increased 
levels of p-CRMP2 in the hippocampus of APPswe/PS1ΔE9 mice at 6 
months of age, which would indicates abundant soluble Aβ in the 
hippocampus (unpublished data). Therefore, CRMP2 phosphorylation may 
possibly be induced by amyloid and/or tau pathologies, and p-tau may be 
essential for the accumulation of p-CRMP2 as well as p-WAVE1 in NFTs 
and/or dystrophic neurites.  
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6.2 The roles of phosphorylated CRMP2, WAVE1 and tau by Cdk5 
and GSK3β in AD model mice. 
In the brains of patients with AD, activity of the kinases Cdk5 and GSK3β 
has been implicated as an important mechanism underlying the regulation 
of axonal transport and cytoskeletal dynamics. This occurs via the 
phosphorylation of molecules that regulate tubulin or actin assembly, such 
as tau, CRMP2, and WAVE1 (Kim et al. 2006;,Plattner et al. 
2006;,Hensley et al. 2011). A previous study showed that the interaction 
between tau and actin may be a critical mediator of tau-induced neuronal 
degeneration (Fulga et al. 2007), and that the phosphorylation of tau by 
GSK3β regulates its axonal transport by controlling its binding to kinesin-1 
(Cuchillo-Ibanez et al. 2008). CRMP2 regulates microtubule dynamics, 
and its functions are regulated by Cdk5 and GSK3β-mediated 
phosphorylation (Hensley et al. 2011). WAVE1 also modulates actin 
assembly and Cdk5-mediated phosphorylation (Kim et al. 2006). Therefore, 
the present study may supports the idea that synaptic dysfunction and 
neuronal degeneration in the brains of patients with AD are induced by 
dysregulation of cytoskeletal regulatory proteins due to abnormal Cdk5 and 
GSK3β activities. Therefore, inhibition of the abnormal activities of these 
kinases may be effective in preventing the progression of AD pathology. 
My present results provide a new insight into the novel therapeutic target 
molecules to prevent tauopathy in the brains of patients with AD. 
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6.3 The effect of ATRA in 3xTg mice. 
Activated Cdk5 inhibits GSK3β kinase activity via an inhibitory serine 
phosphorylation (Plattner et al. 2006), suggesting that the inhibition of 
Cdk5 activity may be sufficient to induce an increase in the activity of 
GSK3β (Hallows et al. 2003). In addition, Vitamin A and β-carotene,  
precursors of vitamin A, in serum concentration are lowed in AD patients 
(Jiménez-Jiménez FJ et al. 1999) and transport of retinoic acid is defective 
in AD patients (Goodman AB et al. 2003). Previous studies showed ATRA 
has a therapeutic effect to amyloid pathology (Ding et al. 2008; Corcoran 
et al. 2004; Kawahara et al. 2014). However, there is no evidence of 
therapeutic effect of ATRA against tau pathology. Therefore, it is 
important to investigate ATRA-based therapy in AD mouse model 
including tau pathology. I thus administrated ATRA, which inhibits the 
phosphorylation of tau by down-regulating the activity of both Cdk5 and 
GSK3β (Ding et al. 2008), to 23-month old 3xTg mice for 4 weeks. My 
results demonstrated that the ATRA treatment reduced tau pathology, and 
that the co-localization of p-tau signals with those of p-CRMP2 or 
p-WAVE1, both phosphorylated by Cdk5, were strongly decreased (Fig. 
4.3). These results are consistent with previous reports in which 
down-regulation of Cdk5 by using RNAi and Cdk5 inhibitory peptide 
ameliorated tau pathology (Piedrahita et al. 2010; He et al. 2017).   
 Decreases in the area and number of activated astrocytes and microglia 
were observed in ATRA-treated 3xTg mice. ATRA has an inhibitory 
production of inflammatory cytokines via binding to RAR or RXR (Dheen 
ST et al. 2005; Mehya et al. 1994). Several cytokines such as IL-6 and 
TGF-β increase activity of Cdk5 (Quintanilla et al. 2004; Utreras et al. 
2012). Thus, down regulation of Cdk5-mediated phosphorylations in its 
substrates by ATRA treatment would be attributed to the anti-inflammatory 
effect of ATRA. Although the molecular mechanisms by which ATRA 
inhibits the activation of astrocytes and microglia is largely unknown, my 
present results support this additional aspect of its therapeutic effect. 
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 ATRA has been approved for therapy of acute promyelocytic leukemia 
(APL) in Japan since 1995. It has been reported that therapy for APL 
patients by ATRA rarely causes serious side effects (Huang et al. 1988). 
Thus, ATRA is possibly useful as a therapeutic drug for AD patients 
through drug repositioning which includes re-investigating of existing 
drugs for new adaptive disorders. Moreover, one of the synthetic retinoids 
Tamibarotene (Am80), an effective drug for ATRA-resistant APL patients, 
is under a clinical trial in Phase 2b as a therapeutic drug for AD.  
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6.4 The role of CRMP2 phosphorylation in the formation of NFT. 
 I elucidated a role of phosphorylation of CRMP2 in tau aggregation of 
hippocampi from 3xTg mice. Interestingly, in the TBS-soluble fraction, 
total tau level was increased in hippocampi of 3xTg:CRMP2KI mice 
compared with 3xTg mice. In addition, total tau level was lowered in 
hippocampi of 3xTg:CRMP2KI in the sarkosyl-insoluble fraction. Since 
phosphorylation level of tau in the TBS-soluble fraction of 
3xTg;CRMP2KI mice was decreased, aggregation of tau might be inhibited. 
These results are consistent with the effect of ATRA. Increase of CRMP2 
phosphorylation has been observed in AD patient and some AD model 
mice which exhibit aggressive amyloid pathology but not in tauopathy 
models such as only overexpressing tauP301L mice (Cole et al. 2007). 
Especially in cerebral cortices of 3xTg mice, phosphorylation of CRMP2 
precedes phosphorylation of tau (Cole et al. 2007). My data suggested that 
CRMP2 phosphorylation might be involved in tau aggregation. Therefore, 
CRMP2 possibly plays a key role to connect amyloid to tau pathology 
mediated by its phosphorylation. However, further experiments are needed 
to determine the mechanism.  
 Although I biochemically analyzed the levels of p-tau and total tau in 
CRMP2 KI mice and WT mice in the TBS-soluble fraction, I couldn’t find 
significant difference as 3xTg mice and 3xTg;CRMP2KI mice showed 
(data not shown). Therefore, pathological conditions, deposition of amyloid 
plaques and/or accumulation of tau, are required to increase total tau level 
and decrease phosphorylation level of tau by elimination of CRMP2 
phosphorylation in the TBS-soluble fraction. As the function of CRMP2 
includes stabilization of microtubule assembly in axon to bind to tubulin 
hetero-dimer, a constitutive active form of CRMP2 may act protectively to 
axonal degeneration and inhibit tau aggregation and phosphorylation of tau 
(Fukata et al. 2002). Although the molecular mechanism is largely 
unknown, histological and biochemical results demonstrated that inhibition 
of CRMP2 phosphorylation attenuated formation of tau aggregates. 
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6.5 Conclusion  
Taken together, I identified several novel NFT-associated molecules, which 
are phosphorylated by Cdk5 and GSK3β, similar to tau. These molecules 
provide targets for interventions aimed at reducing tau pathology. ATRA 
attenuated the formation of NFTs by down-regulation of Cdk5 and GSK3β 
and suppressed the activation of astrocytes and microglia in area CA1 of 
the hippocampus. These results support ATRA as an effective compound 
for the treatment of AD. Moreover, inhibition of CRMP2 phosphorylation 
by Cdk5 could be a novel preventive approach for tau pathology in AD. 
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